Phase I/IIa Intrathecal Gene Delivery Clinical Trial for IGHMBP2-Related Diseases
Latest Information Update: 13 Oct 2025
At a glance
- Drugs ACTX-401 (Primary)
- Indications Charcot-Marie-Tooth disease; Respiratory distress syndrome; Spinal muscular atrophy
- Focus Adverse reactions
Most Recent Events
- 30 Sep 2025 Planned End Date changed from 1 Nov 2028 to 1 Jul 2030.
- 30 Sep 2025 Planned primary completion date changed from 1 Nov 2026 to 1 Jul 2028.
- 16 Dec 2021 New trial record